XBIT - XBiotech Inc.

2.33
-0.020   -0.858%

Share volume: 13,920
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$2.35
-0.02
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 1%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.85%
1 Month
-1.69%
3 Months
-8.63%
6 Months
-17.38%
1 Year
-26.73%
2 Year
-63.31%
Key data
Stock price
$2.33
P/E Ratio 
0.00
DAY RANGE
$2.33 - $2.38
EPS 
-$0.96
52 WEEK RANGE
$2.09 - $3.62
52 WEEK CHANGE
-$29.18
MARKET CAP 
81.097 M
YIELD 
N/A
SHARES OUTSTANDING 
30.488 M
DIVIDEND
$2.0995
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
0.92
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$29,608
AVERAGE 30 VOLUME 
$26,083
Company detail
CEO: John Simard
Region: US
Website: xbiotech.com
Employees: 100
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis.

Recent news